BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors

Expert Opinion on Investigational Drugs

Volumn 25, Issue 1, 2016, Pages 7-14

  Preusser, Matthias ^a   Bienkowski, Michal ^b,c   Birner, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

BRAF; brain tumors; glioma; inhibition

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; B RAF KINASE V600; DABRAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUROEPITHELIOMA; NONHUMAN; OLIGODENDROGLIOMA; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; POINT MUTATION; PRIMARY NEUROEPITHELIAL BRAIN TUMOR; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; GANGLIOGLIOMA; GENETICS; NEOPLASMS, NEUROEPITHELIAL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GANGLIOGLIOMA; GLIOMA; HUMANS; NEOPLASMS, NEUROEPITHELIAL; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84954338858     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1110143     Document Type: Review

References (67)

1. Louis D, Ohgaki H, Wiestler O, et al. World Health Organization classification of tumours of the central nervous system. Lyon: IARC; 2007.
2. Soffietti R, Baumert B, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO∗Task Force. Eur J Neurol. 2010;17:1124-1133.
3. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15: e395-403.
4. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
5. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.
6. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462-477.
7. Brat DJ, Verhaak RGW, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481-2498.
8. Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol. 2014;27:689-696.
9. Myung JK, Cho H, Park C-K, et al. Analysis of the BRAF V600E mutation in central nervous system tumors. Transl Oncol. 2012;5:430-436.
10. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397-405.This paper presents a screening of a large cohort of CNS tumor patients for BRAF mutations, which offers substantial information on their frequency in different tumors.
11. Dahiya S, Emnett RJ, Haydon DH, et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol. 2014;16:318-319.
12. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6:e17948.
13. Nobusawa S, Hirato J, Kurihara H, et al. Intratumoral heterogeneity of genomic imbalance in a case of epithelioid glioblastoma with BRAF V600E mutation. Brain Pathol. 2014;24:239-246.
14. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011;17:7595-7604.
15. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118:401-405.
16. Jones DTW, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-8677.
17. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol. 2012;71:66-72.
18. Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, et al. Pediatric brainstem gangliogliomas show BRAFV600E mutation in a high percentage of cases. Brain Pathol. 2014;24:173-183.
19. Dimitriadis E, Alexiou GA, Tsotsou P, et al. BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors. J Neurooncol. 2013;113:353-358.
20. Chapp? C, Padovani L, Scavarda D, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013;23:574-583.
21. Koelsche C, Sahm F, W?hrer A, et al. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol. 2014;24:221-229.
22. Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, et al. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol. 2013;111:59-69.
23. Koelsche C, W?hrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 2013;125:891-900.
24. Lindsay AJ, Rush SZ, Fenton LZ. Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status. J Neurooncol. 2014;118:395-404.
25. Koelsche C, Sahm F, Paulus W, et al. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol. 2014;40:337-344.
26. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-736.
27. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
28. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-332.
29. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
30. S?nchez-Torres JM, Viteri S, Molina MA, et al. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244-250.
31. Schmid S, Siano M, Joerger M, et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer. 2015;87:85-87.
32. Yaeger R, Cercek A, O'Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21:1313-1320.
33. Ramanujam S, Schadendorf D, Long GV. Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol. 2015;4:25.
34. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50:611-621.
35. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901.
36. Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014;20:18-24.
37. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436-444.
38. Robinson SD, O'Shaughnessy JA, Cowey CL, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer. 2014;85:326-330.
39. Capper D, Berghoff A-S, von Deimling A, Preusser M. Clinical neuropathology practice news 2-2012: BRAF V600E testing. Clin Neuropathol. 2012;31:64-66.
40. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16(Suppl 4):iv1-63
41. Desjardins A. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? Nat Rev Neurol. 2015;11:429-430.
42. Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;139. DOI:10.1038/nrneurol.2015.
43. Reardon DA, Schuster JM, Tran DD, et al. 107 ReACT: Overall survival from a randomized Phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Neurosurgery. 2015;62(Suppl 1):198-199.
44. Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. Neuro Oncol. 2015;17:854-861.
45. Gan HK, Papadopoulos KP, Fichtel L, et al. Phase I study of ABT-414 mono-or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). J Clin Oncol. 2015;33(suppl; abstr 2016).
46. Zelboraf Label Information. FDA/center for drug evaluation and research. 2015 [cited 2015 Aug 28]. Available from: Http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/202429s000lbl.pdf
47. Tefinlar Label Information. FDA/center for drug evaluation and research. 2014 [cited 2015 Aug 28]. Available from: Http://www.accessdata.fda.gov/drugsatfda- docs/label/2014/202806s002lbl.pdf
48. Li M, Wei M, Jiang Z. BRAF overexpression induces rampant glioma proliferation independent of phospho-EGFR expression. Adv Clin Exp Med. 2014;23:893-899.
49. Ahn J-H, Lee YW, Ahn SK, et al. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Life Sci. 2014;104:38-46.
50. Yao T-W, Zhang J, Prados M, et al. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;26:21993-2005.
51. Skrypek M, Foreman N, Guillaume D, et al. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer. 2014;61:2099-2100.
52. Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14:258.
53. West ES, Williams VL, Morelli JG. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma. Pediatr Dermatol. 2015;32:153-154.
54. Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61:1101-1103.
55. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: A retrospective case series. J Neurooncol. 2013;114:237-240.
56. Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol. 2013;31: E159-60.
57. Shih KC, Shastry M, Williams JT, et al. Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma. J Clin Oncol. 2014;32:e98-e100.
58. Del Bufalo F, Carai A, Fig?-Talamanca L, et al. Response of recurrent BRAFV600E mutated ganglioglioma to vemurafenib as single agent. J Transl Med. 2014;12:356.
59. Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol. 2015;39:528-540.
60. Lee EQ, Ruland S, LeBoeuf NR, et al. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol. 2014. DOI:10.1200/JCO.2013.51.1766.
61. Harding JJ, Catalanotti F, Munhoz RR, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist. 2015;20:789-797.
62. Hecht M, Zimmer L, Loquai C, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26:1238-1244.
63. Wallach JB, Rietschel P, Kalnicki S, et al. BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Pract Radiat Oncol. 2014;4:e213-6.
64. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
65. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
66. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
67. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.